|

VIR-2218 and peginterferon alfa-2a Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1

Indications

  • Liver Disease1
  • Chronic Hepatitis b1

Bethesda, Maryland1 trial

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

National Institutes of Health Clinical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.